Form 4: Precision BioSciences CFO John Alexander Kelly Reports Acquisition of Restricted Stock Units
SEC Form 4 Filing
Chief Financial Officer of Precision BioSciences, John Alexander Kelly, reports the acquisition of 41,705 restricted stock units.
Summary
- On April 18, 2024, John Alexander Kelly, the Chief Financial Officer of Precision BioSciences, acquired 41,705 restricted stock units (RSUs).
- Each RSU represents a contingent right to receive one share of Precision BioSciences' Common Stock.
- The award vests in three substantially equal annual installments beginning on January 20, 2025, contingent upon Kelly's continued service to the company.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices and incentivizes management alignment with shareholder interests.
Positives
- The vesting schedule incentivizes continued service of the CFO.
Future Outlook
The RSUs will vest over the next three years, incentivizing the CFO to remain with the company.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates compensation in the form of equity.
Stakeholder Impact
- Shareholders may view this as a positive sign, aligning management's interests with the company's long-term performance.
Key Dates
| Date | Description |
|---|---|
| 04/18/2024 | Date of transaction: CFO acquired restricted stock units |
| 04/22/2024 | Date of report filing |
| 01/20/2025 | First vesting date for the restricted stock units |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.